Delving into the Latest Updates on Ketamine Hydrochloride with Synapse

Overview

Basic Info

SummaryKetamine is a small molecule drug that acts as a modulator at the N-methyl-D-aspartate (NMDA) receptor. It is marketed under the trade name KETALAR and is primarily used as an anesthetic drug. Ketamine was first approved for medical use in the United States in 1970 by Endo International. This drug is available as a slightly acidic, sterile solution for intravenous or intramuscular injection. Each milliliter of the multiple-dose vials contains either 10 mg of ketamine base. Ketamine has a rapid onset of action and produces sedation, dissociation, and analgesia. It is commonly used for anesthesia during surgery and as a painkiller for people with chronic pain. Ketamine may have some potential as an antidepressant, but more research is needed to determine its efficacy and safety for this indication. The use of ketamine as an anesthetic or painkiller may cause some side effects, including hallucinations, nausea, and vomiting.

Drug Type

Small molecule drug

Synonyms

(+-)-Ketamine, (±)-ketamine, 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone

+ [38]

Target

NMDA receptor

Action

modulators

Mechanism

NMDA receptor modulators(Glutamate [NMDA] receptor modulators)

Therapeutic Areas

Nervous System DiseasesOther DiseasesCongenital Disorders+ [5]

Active Indication

PainAnesthesiaBipolar and Related Disorders+ [18]

Inactive Indication

Amyotrophic Lateral SclerosisAutism Spectrum DisorderBunion+ [5]

Originator Organization

Endo International Plc

Active Organization

Wuhan Jiuan Medicine Industry Co. Ltd.

Consegna Pharma, Inc.

Pharmather, Inc.

+ [17]

Inactive Organization

Douglas Pharmaceuticals Ltd.Cch Pharma Pty Ltd.Novartis Pharma AG

+ [2]

License Organization

Seelos Therapeutics, Inc.

Nephron Pharmaceuticals Corp.

Kymanox Corp.

+ [10]

Drug Highest PhaseApproved

First Approval Date

United States (19 Feb 1970),

Anesthesia

RegulationFast Track (United States), Orphan Drug (United States), Innovative Licensing and Access Pathway (United Kingdom)

Login to view timeline

Structure/Sequence

Molecular FormulaC13H17Cl2NO

InChIKeyVCMGMSHEPQENPE-UHFFFAOYSA-N

CAS Registry1867-66-9

The goal of this clinical trial is to learn if nebulized ketamine helps treat moderate to severe asthma attacks in adults in the emergency department. It will also learn about the safety of ketamine when inhaled through a nebulizer.
The main questions it aims to answer are:
* Does nebulized ketamine improve breathing more than standard treatment alone?
* What side effects, if any, do participants experience after receiving nebulized ketamine?
Researchers will compare nebulized ketamine to a placebo (a saltwater mist with no medication) to see how well it works and how safe it is.
Participants will:
* Receive either nebulized ketamine or a placebo mist, along with standard asthma treatment
* Have their breathing checked before and after treatment using a peak flow meter
* Be monitored for 60 minutes and have their symptoms, vital signs, and any side effects recorded

Start Date01 Sep 2026

Sponsor / Collaborator-

100 Clinical Results associated with Ketamine Hydrochloride

Login to view more data

100 Translational Medicine associated with Ketamine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Ketamine Hydrochloride

Login to view more data

31,712

Literatures (Medical) associated with Ketamine Hydrochloride

01 Feb 2026·Biomaterials advances

Multimodal topical gel combining 2-hydroxyflavanone, gabapentin, and ketamine alleviates diabetic vulvodynia and allodynia with concurrent tissue regeneration in streptozocin-induced rat models

Article

Author: Bashir, Nasreena ; Ayyaz, Fatima ; Ali, Gowhar ; Islam, Nazar-Ul- ; Ayaz, Muhammad ; Mir, Mushtaq Ahmad ; Qayyum, Jibran ; Khan, Pordil

Neuropathic pain arises from damage or illness affecting either central or peripheral or both somatosensory systems. Vulvodynia, a chronic neuropathic pain disorder in women, remains largely neglected despite its significant impact. This study was aimed to evaluate safety and efficacy of a multimodal analgesic gel (MMG-10 %) in relieving diabetic neuropathic pain; specifically vulvodynia and allodynia in female rats. We have formulated a highly promising flavonoid, 2'-Hydroxyflavanone (2-HF) with gabapentin and ketamine. Streptozotocin-induced Diabetes Mellitus (DM) was used as a painful neuropathic model. Static and dynamic vulvodynia and allodynia were assessed using parameters including Flinching Response Threshold (FRT), Paw Withdrawal Threshold (PWT), Flinching Response Latency (FRL) and Paw withdrawal Latency (PWL) by applying the stimuli of Von Frey Filaments to the vulvar region and hind mid-planter regions of paws. A uniform quantity for five consecutive days post 29 days of MMG-10 % and control gel (1.0 mg/cm²) was applied three times daily (TDS) on vulvar area for vulvodynia and mid-plantar paws for allodynia studies. Safety with respect to sensorimotor functions was assessed via Rota rod and Balance beam tests. We conducted the vulvar histological tissue study to evaluate diabetes-induced structural damage and assess the therapeutic potential of a multimodal gel in tissue regeneration. Treatment with tested MMG 10 % resulted in a significant increase in FRT, PWT, FRL and PWL respectively (***p < 0.001, ** p < 0.01, p > 0.05) compared to the STZ treated group. Falling latency time was not affected in all treated groups exhibiting sensorimotor safety. The multimodal gel demonstrated significant regenerative efficacy by reducing atrophy, desquamation, and hyperkeratosis, effectively restoring vulvar tissue integrity in diabetic animals. Our MMG-10 %) could be potentially an effective therapeutic remedy for the relief against diabetes-induced vulvodynia and allodynia.

01 Jan 2026·INTERNATIONAL JOURNAL OF CARDIOLOGY

Feasibility and safety of ketamine for procedural sedation in pediatric patients undergoing electrophysiology procedures: A cohort study

Article

Author: Barengo, Alberto ; Barca, Luca ; Monaco, Fabrizio ; Fioravanti, Francesco ; Della Bella, Paolo Emilio ; Schiavone, Marco ; Rampa, Lorenzo ; Caparra, Francesca ; Paglino, Gabriele ; Tanese, Nikita ; Bisceglia, Caterina ; Martello, Valentina ; Gulletta, Simone ; Forleo, Giovanni Battista ; D'Andria Ursoleo, Jacopo

INTRODUCTION:

Electrophysiology (EP) procedures in the pediatric population are often performed aided by anesthetic support under general anesthesia (GA), provided they require a delicate balance between appropriate sedation depth, analgesia, immobility, and hemodynamic stability. GA is still the standard of care but shows several limitations. Ketamine sedation (KS) offers an alternative to GA with preserved respiratory and cardiovascular function, yet its role in pediatric EP procedures remains understudied.

METHODS:

We retrospectively included 217 consecutive pediatric patients (<18 years) who underwent their first EP procedure at our center between 2016 and 2024. Patients received either KS (n = 37) or GA (n = 180) based on anesthesiologist and cardiologist preference. Primary endpoints were the GA conversion rate, perioperative complications, "door-to-door" operating room occupation time and postprocedural recovery time. Secondary endpoints included results of the electrophysiology study (EPS), change in electrocardiography parameters before, during and after drug infusion and difference of vital signs behavior between the two groups. Propensity score matching (PSM) was performed to correct for age, body mass index (BMI), type of procedure and sex.

RESULTS:

Before PSM, compared with the GA group, the KS cohort was older (mean age 13.5 ± 4.5 vs. 11.3 ± 3.2 years in GA; p = 0.02), while sex distribution and BMI were similar. After PSM, there were no significant differences between the tested variables. No KS patient required GA conversion or experienced complications (e.g., emergence delirium). Shorter operating room door-to-door occupation time (KS 79.3 ± 47.2 min; p = 0.0026 vs GA 100.8 ± 37.2 min) and shorter recovery room time were reported in the KS group compared to the GA group (15 ± 19 min vs 41.5 ± 14 min; p = 0.001). No significant differences in the EPS result was observed between the two groups (19.4 % vs. 22.7 %; p = 0.59). In KS patients, electrocardiographic parameters remained stable before, during and at the end of procedure.

CONCLUSIONS:

Ketamine-based sedation is a safe and effective alternative to GA for pediatric EP procedures, maintaining hemodynamic and electrocardiographic stability. Moreover, KS enhances operating room efficiency by reducing both periprocedural and recovery times.

01 Jan 2026·JOURNAL OF AFFECTIVE DISORDERS

Ketamine-induced re-organisation of neural oscillations across health, MDD, and TRD: A systematic review of magnetoencephalography insights

Review

Author: Yu, Ying ; Zhang, Xinbi ; Huang, Mingming ; Xu, Wangyang ; Zeng, Jia ; Di, Leiming

Sub-anesthetic ketamine (KT) has become a promising rapid-acting antidepressant candidate, yet its mechanisms have not been comprehensively defined. Magnetoencephalography (MEG) provides millisecond recordings of cortical rhythms, exposing the rapid glutamatergic dynamics underlying ketamine's action. We synthesized evidence on KT-induced oscillatory and connectivity changes in healthy volunteers (HVs), major depressive disorder (MDD) and treatment-resistant depression (TRD), relating neural signatures to symptomatic relief. Following PRISMA and a PROSPERO-registered protocol (CRD42024609670), five databases were searched to June 2025; eighteen eligible trials (605 adults: 242 HVs, 176 MDD, 172 TRD; 41.65 % female; mean Jadad = 3.3) administered intravenous KT ≤ 0.5 mg/kg and reported MEG outcomes. Exploratory trials indicate that a single ketamine infusion reduces MADRS scores by 10-12 points within 4-9 h in MDD and TRD and improves anxiety, psychosis and suicidality, although small sample sizes limit generalisability. MEG studies consistently report increased gamma-band (30-90 Hz) power, posterior alpha and beta suppression, reduced envelope connectivity and enhanced directed flow in thalamocortical and frontoparietal networks, glutamatergic disinhibition and network renormalisation. Task-evoked data show larger M100 and M170 responses, stronger NMDA-mediated feed-forward drive from somatosensory to inferior-frontal cortex and limbic gamma modulation. Preliminary markers such as higher pre-infusion anterior cingulate activity, elevated baseline gamma power and reduced pgACC beta rebound in responders versus delta and alpha coupling in non-responders require validation in larger cohorts and meta-analyses. KT appears to induce a reproducible MEG signature that may track and potentially forecast its rapid antidepressant effects, but such predictive claims remain provisional pending rigorous replication.

738

News (Medical) associated with Ketamine Hydrochloride

20 Oct 2025

·www.pharmaceutical-technology.com

Infertility treatment heads first drugs on FDA’s new priority review scheme

Pharma companies wishing to reap the benefits of the programme need to demonstrate US-centric potential for their drug candidates. kemalbas via GettyImages. The US Food and Drug Administration (FDA) has selected the first products to be included on the Commissioner’s National Priority Voucher (CNPV) pilot programme. A total of nine drug candidates have joined the scheme launched in June 2025 , which will see its developers receive a voucher that will significantly expedite their path to approval. The group is headed by Merck’s Pergoveris (follitropin alfa/lutropin alfa), which is already approved in Europe, for the treatment of infertility. President Donald Trump specifically identified Pergoveris’ inclusion, touting the drug’s potential to offer a cheaper option to US patients. “This drug would directly compete against a much more expensive option that currently has a monopoly in the American market, and this will bring down costs very significantly,” Trump said during an IVF news conference at the White House. Trump was likely referring to Gonal-f, made by Merck’s US and Canadian healthcare business EMD Serono. Gonal-f generated global sales of €833m in 2024. The pharma company plans to use its CNPV to file for FDA approval of its new drug, which it disclosed while announcing a broader deal with the US government to expand fertility access treatment. Elsewhere on the list, candidates being developed for hearing and vision loss have been included in the form of Regeneron’s gene therapy DB-OTO and Dompé Farmaceutici’s Oxervate (cenegermin-bkbj), respectively. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Sanofi’s teplizumab, which is already FDA-approved to delay the onset of stage 3 type 1 diabetes, has been included on the list. The agency said it was selected for “type 1 diabetes,” hinting that the review could be for a broader label approval. Revolution Therapeutics’ RMC-6236, in development for the treatment of pancreatic cancer, and Disc Medicine’s porphyria therapy bitopertin round off the list of products for specific diseases. The FDA selected cytisinicline for nicotine vaping addiction, while ketamine and Augmentin XR were chosen to boost domestic manufacturing of anaesthesia and antibiotics, respectively. The CNPV programme is the latest move by the Trump administration to bolster its pharmaceutical armoury and incentivise the development of new drugs specifically for Americans . Pharma companies wishing to reap the benefits of the programme need to demonstrate US-centric potential for their drug candidates. Therapies need to address a health crisis in the country, produce an innovative cure for American patients, meet public health needs, or increase domestic drug manufacturing as a national security issue. In its statement sharing the first batch of recipients, the FDA said that each product has significant potential to address one or more of these major national priorities. The agency stated that it would likely add another group of CNPV recipients in the coming months. Companies with a product in the programme will receive a decision within 1-2 months, compared to the usual 10-12 months, following filing of a complete application for a drug or biologic. Sponsors will also be able to undertake enhanced feedback with FDA staff during development and the review window. “One of our core goals is to deliver more cures and meaningful treatments – especially ones that have an outsized impact on our most pressing national priorities. We must modernise the review process and try new approaches to meet the needs of the American people,” said FDA commissioner Marty Makary. While the CNPV pilot begins its journey in the US regulatory landscape, experts have been concerned that its activity could take attention away from similar programmes that incentivise rare diseases. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

Drug ApprovalPriority Review

17 Oct 2025

·www.fiercebiotech.com

FDA names 9 first recipients of 1- to 2-month priority review vouchers

Revolution Medicines and Disc Medicine are among the recipients of a Commissioner’s National Priority Voucher. \n The FDA has handed out the first nine national priority vouchers, positioning companies including Merck KGaA, Regeneron and Sanofi to complete the approval process in one to two months.FDA Commissioner Marty Makary, M.D., launched the program in June, and the agency began accepting applications in July. The program is designed to cut product approval times, which are typically 10 to 12 months, for medicines that align with U.S. national priorities. Specific priorities include addressing the U.S. public health crisis, treating large unmet medical needs and delivering transformative treatments.The first nine recipients of a Commissioner’s National Priority Voucher (CNPV) are a mix of approved drugs and investigational medicines. The investigational products include DB-OTO, the gene therapy that Regeneron is developing to treat a rare genetic form of hearing loss. Regeneron plans to seek FDA approval this year. If the CNPV works as intended, the timeline suggests the gene therapy could come to market early next year at the latest. The company has published data on the gene therapy in 12 patients, nine of whom only received the treatment in one ear. Talking on an FDA podcast, Mallika Mundkur, M.D., who leads the CNPV program at the agency, said the DB-OTO data are “pretty remarkable” but cautioned that “we need to learn more about” its safety. The podcast was hosted by Makary, who said the hearing restoration data point to the need for the FDA “to get a decision out promptly using the standard scientific process, cutting any wasted time.” Makary added that “we\'re hearing the company may make it available either at an extremely low price or for free, which of course is part of a national priority to make drugs more affordable.” The criteria for the CNPV program include lowering the U.S. price of a drug consistent with most-favored nation pricing.Revolution Medicines’ RMC-6236 and Disc Medicine’s bitopertin are among the other recipients of a CNPV. RMC-6236, also called daraxonrasib, is a RAS-MULTI(ON) inhibitor that is in phase 3 development as a treatment for forms of pancreatic and non-small cell lung cancer. Data from one of the trials are due next year. Revolution is holding off on adjusting its timelines while it assesses the impact of the voucher.Discussing RMC-6236 on the podcast, Makary said the FDA’s oncology division “thought this is something that is potentially promising.” The FDA commissioner went on to say the agency is going into its divisions and asking reviewers what programs they think “may potentially look amazing.” Makary framed the talks as a push for the FDA to move beyond “receive-only mode” when identifying assets it can accelerate. Meanwhile, Disc\'s bitopertin is a GlyT1 inhibitor being assessed in rare, genetically driven hematologic diseases. The biotech filed for accelerated FDA approval of the small molecule last month. Disc originally applied for a priority review that would reduce the review time from 10 months to six months. The FDA also awarded CNPVs to Merck’s pergoveris and Sanofi’s teplizumab. Pergoveris, a fertility drug, is already available in 74 countries. Merck plans to file for FDA approval of the drug using its CNPV, which it disclosed as part of a broader deal with the U.S. government to expand access to fertility treatment. Teplizumab, which Sanofi sells as Tzield, is FDA-approved to delay the onset of forms of Type 1 diabetes.Officials gave another two CNPVs to cytisinicline for nicotine vaping addiction and cenegermin-bkbj for blindness. Achieve Life Sciences is seeking approval of cytisinicline for smoking cessation. Cenegermin is already sold as Oxervate by Dompé Farmaceutici to treat a corneal disease. The final two CNPVs are focused on onshoring, with the FDA using the vouchers to try to boost domestic production of ketamine for general anesthesia and of the antibiotic augmentin XR. Phlow received the ketamine CNPV.

Phase 3Priority ReviewDrug Approval

17 Oct 2025

·firstwordpharma.com

TrumpRx welcomes Merck KgaA, one of nine to receive new priority voucher

Merck KGaA is the latest drugmaker to slash some of its products' US list prices in exchange for an exemption from President Donald Trump's 100% pharmaceutical tariff — and one of the first to receive a new kind of speedy review voucher from the FDA.The third pharma to reach a most-favoured nation (MFN) drug pricing deal with the Trump administration, Merck — through its US-based healthcare business unit, EMD Serono — will make its in vitro fertilization (IVF) therapies available through a direct-to-consumer (DTC) platform that patients with prescriptions will be able to reach via the government-run TrumpRx website, due to launch in January. The company said on Thursday that if all three of its IVF offerings — Gonal-f (follitropin alfa injection), Ovidrel (choriogonadotropin alfa injection) and Cetrotide (cetrorelix acetate for injection) — are used in a single IVF protocol, patients will pay 84% less than the total list price. While AstraZeneca's and Pfizer's respective MFN deals earned them each a three-year grace period from tariffs, Merck said in a release that its pharmaceutical products and ingredients will be excluded from tariffs, without a time limit, "provided EMD Serono invests in future biopharmaceutical manufacturing and research in the United States."The German drugmaker "look[s] forward to growing our footprint here even further with future fertility manufacturing," said Belén Garijo, CEO and chair of Merck, in a company release.A new kind of priority reviewAnd more fertility options for US patients are on the way. In conjunction with the MFN deal, Merck also announced that it's part of the inaugural cohort of companies to receive one of the FDA's new Commissioner’s National Priority Vouchers (CNPVs). The pharma plans to use its voucher to accelerate review of Pergoveris, an IVF therapy that combines recombinant human follicle stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH) in a single injection pen. The product has been approved in Europe since 2017. With the CNPV, Merck is promised a regulatory decision on Pergoveris within one to two months after filing the application, along with "enhanced" communication with FDA staff during the review process. The US regulator had said in June it planned to start handing out CNPVs to drugmakers "addressing our most important US national priorities," either by attempting to solve a health crisis, upping domestic manufacturing or developing an innovative treatment. In July, FDA Commissioner Marty Makary suggested that companies that promise to "equalise" the cost of their drugs between the US and other countries could also qualify for a CNPV.In addition to Merck's Pergoveris, the FDA on Thursday revealed eight other products that have earned a CNPV, including Regeneron's hearing loss gene therapy DB-OTO; the company had announced plans to file for FDA approval of the one-time treatment just days earlier.Another CNPV went to Sanofi's anti-CD38 antibody teplizumab to treat type 1 diabetes. Initially approved by the FDA in 2022 to delay the onset of stage 3 type 1 diabetes in adults and children aged 8 years and older who have stage 2 disease, the French pharma gained teplizumab through its $2.9-billion takeout of Provention Bio in 2023.Revolution Medicines has snagged a voucher for pancreatic cancer treatment daraxonrasib (RMC-6236); it started a registrational trial of the pan-RAS inhibitor in October 2024. Disc Medicines will get a fast review for bitopertin, having just submitted an application on Sept. 30 for the oral GlyT1 inhibitor to treat erythropoietic protoporphyria, including X-linked protoporphyria.FDA approved for neurotrophic keratitis in 2018, Dompé Farmaceutici's cenegermin received a voucher for blindness. Other recipients include Achieve Life Sciences' nicotine vaping addiction treatment cytisinicline, as well as domestically manufactured versions of ketamine and Augmentin XR, an antibiotic.

Drug ApprovalPriority Review

100 Deals associated with Ketamine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00711	Ketamine Hydrochloride	N01AX03	DBSALT000396

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pain	United States	Pharmather Holdings Ltd.	08 Aug 2025
Anesthesia	United States	Ph Healthcare Services	19 Feb 1970

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bipolar and Related Disorders	Phase 3	United States	NeuroRx, Inc.	30 Jan 2022
Bipolar Disorder	Phase 3	United States	NeuroRx, Inc.	25 Jun 2019
Suicidal Ideation	Phase 3	United States	NeuroRx, Inc.	25 Jun 2019
Alcohol Use Disorder	Phase 3	United Kingdom	Awakn Life Sciences Corp.	-
Stress Disorders, Post-Traumatic	Phase 2	United States	Seelos Therapeutics, Inc.	27 Nov 2023
Rett Syndrome	Phase 2	United States	Pharmather Holdings Ltd.	02 Feb 2023
Dyskinesia, Drug-Induced	Phase 2	United States	Pharmather, Inc.	05 Oct 2021
Parkinson Disease	Phase 2	United States	Pharmather, Inc.	05 Oct 2021
Cluster Headache	Phase 2	Denmark	Cch Pharma Pty Ltd.	20 Nov 2019
Depressive Disorder, Major	Phase 2	Australia	Douglas Pharmaceuticals Ltd.	30 May 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06588907 (Pubmed \| Am J Emerg Med)	Not Applicable	Pain	85	Procedural Sedation and Analgesia (PSA) with Ketamine	psqpmffhly(dhqliczvrs) = higher in the PSA group otuttoxzxx (fvxzislhhv ) View more	Positive	01 Oct 2025
				Infraclavicular Block (IB)
NCT05907213 (CTgov)	Phase 1	Depression, Postpartum \| Pain, Postoperative	12	Dose Level 1 (Ketamine (Ketalar) Dose Level 1)	opkcnzxbew = fjeobivuef hsrsavpbxy (locrzychjb, quducfikul - lnkfweamiq) View more	-	12 Sep 2025
				Ketamine (Ketalar) Dose Level 2 (Ketamine (Ketalar) Dose Level 2)	opkcnzxbew = rguwbrfhwa hsrsavpbxy (locrzychjb, jmufavuzmw - egrmpeggzl) View more
NCT00210210 (KETAMINE, CTgov)	Phase 3	Breast Cancer \| Pain, Postoperative	230	ketamine (Ketamine Arm)	macdoyoraf = mbisjnowtz kycamazdyn (gonnoczzxs, ftdvqrbbyk - dedxxlrssq) View more	-	08 Sep 2025
				Saline solution (Reference Arm)	macdoyoraf = hxxyhnhtal kycamazdyn (gonnoczzxs, skynjaibva - zqwrgkdyqc) View more
NCT04226963 (Pubmed \| Neuropsychopharmacol Rep)	Not Applicable	Depressive Disorder, Treatment-Resistant	35	Intravenous 0.5 mg/kg Ketamine	ihnerqcots(tvpiwmerlj) = kzbplhlwdm ahcseionqh (ihvkbocnqd ) View more	Positive	01 Sep 2025
				Oral 2.0/2.5 mg/kg Ketamine	ihnerqcots(tvpiwmerlj) = nrqbjrbdpb ahcseionqh (ihvkbocnqd ) View more
NCT04625283 (IMPAKT ERAS, Pubmed \| Br J Anaesth)	Phase 4	-	1,522	Ketamine	cleapxhrzh(kcuxgdghew): OR = 2.03 (95.0% CI, 1.14 - 3.63) View more	Negative	01 Sep 2025
				Saline placebo
NCT04613453 (CTgov)	Phase 2	Depressive Disorder \| Depressive Disorder, Major	12	Ketamine Infusion (Ketamine Infusion)	oguwrsarki(hjerhecpkg) = gtkrclrqbd umgjhpjjtu (obnblzprcz, 1.34) View more	-	26 Aug 2025
				Midazolam Infusion (Midazolam Infusion)	oguwrsarki(hjerhecpkg) = zavxefmnoq umgjhpjjtu (obnblzprcz, 1.37) View more
NCT05796791 (CTgov)	Early Phase 1	Smoking Cessation \| Nicotine Dependence	7	Motivational enhancement therapy+Ketamine Hydrochloride	erallgihzf = amajtnhjsx ynbqckmnoy (dlibpuomuh, vrrfiuhomq - ozsczymdxj) View more	-	18 Jul 2025
NCT03431285 (CTgov)	Not Applicable	Vaso-occlusive crisis \| Pain \| Anemia, Sickle Cell	278	standard IV hydration+Morphine (Morphine Group)	efzahqbmbm(oeauzuaonm) = kdffqlubir xryruxxhdn (ewognnslbu, 1.90) View more	-	28 May 2025
				standard IV hydration+Ketamine Group (Ketamine Group)	efzahqbmbm(oeauzuaonm) = kzuorbljnf xryruxxhdn (ewognnslbu, 2.13) View more
NCT06001372 (TREK, CTgov)	Early Phase 1	Anxiety Disorders \| Gastrointestinal Neoplasms	2	Ketamine	pzofplmeym = uxhmzyrxcw iznqairwuk (jsjnquavgr, yrrawefiql - nfuxzoooyv) View more	-	16 Apr 2025
NCT04141696 (CTgov)	Phase 1/2	Fatigue	10	Ketamine (Ketamine Administration)	znhpedcmmu(whjyafergy) = umzcdycbxe fibeluzddc (ipvxmbssml, kgezfyzqln - flajnrjshu) View more	-	15 Apr 2025
				Midazolam (Midazolam Administration)	znhpedcmmu(whjyafergy) = ifvsbxuxxy fibeluzddc (ipvxmbssml, kcxskgbaym - gfjgpwfwva) View more